Health System Performance for Multimorbid Cardiometabolic Disease in India: A Population-Based Cross-Sectional Study.
India
cardiometabolic diseases
health system performance
multimorbidity
Journal
Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
04
2021
accepted:
20
12
2021
entrez:
17
2
2022
pubmed:
18
2
2022
medline:
1
3
2022
Statut:
epublish
Résumé
The prevalence of multimorbidity in low- and middle-income countries (LMICs) is thought to be rising rapidly. Research on the state of healthcare for multimorbidity in LMICs is needed to provide an impetus for integration of care across conditions, a baseline to monitor progress, and information for targeting of interventions to those most in need. Focusing on multimorbid cardiometabolic disease in India, this study thus aimed to determine 1) the proportion of adults with co-morbid diabetes and hypertension who successfully completed each step of the chronic disease care continuum from diagnosis to control for both conditions, and 2) how having additional cardiovascular disease (CVD) risk factors is associated with health system performance along the care continuum for diabetes, hypertension, and co-morbid diabetes and hypertension. Using a nationally representative household survey carried out in 2015 and 2016 among women aged 15-49 years and men aged 15-54 years, we created a 'cascade of care' for diabetes, hypertension, and co-morbid diabetes and hypertension by determining the proportion of those with the condition who had been diagnosed, were on treatment, and achieved control. We used Poisson regression with a robust error structure to estimate how having additional cardiovascular disease (CVD) risk factors (diabetes, hypertension, current smoking, and obesity) was associated with reaching each cascade step for diabetes, hypertension, and co-morbid diabetes and hypertension. Seven hundred thirty-four thousand seven hundred ninety-four adults were included in the analysis. Among individuals with co-morbid diabetes and hypertension, 28·8% (95% CI, 26·7%-31·0%), 16·1% (95% CI, 14·4%-17·9%), and 3·7% (95% CI, 2·8%-4·9%) - with these proportions varying between states by a factor of 4·8, 7·9, and 56·8 - were aware, treated, and achieved control of both conditions, respectively. Men, adults with lower household wealth, and those living in rural areas were less likely to reach each cascade step. Having additional CVD risk factors generally did not increase the probability of reaching each cascade step for diabetes, hypertension, and co-morbid diabetes and hypertension, except that having concurrent diabetes increased the probability of successfully transitioning through the hypertension care cascade. While varying widely between states and population groups, health system performance for co-morbid diabetes and hypertension is generally low in India, and there appears to be little integration of care across CVD risk factors. European Research Council.
Sections du résumé
Background
The prevalence of multimorbidity in low- and middle-income countries (LMICs) is thought to be rising rapidly. Research on the state of healthcare for multimorbidity in LMICs is needed to provide an impetus for integration of care across conditions, a baseline to monitor progress, and information for targeting of interventions to those most in need. Focusing on multimorbid cardiometabolic disease in India, this study thus aimed to determine 1) the proportion of adults with co-morbid diabetes and hypertension who successfully completed each step of the chronic disease care continuum from diagnosis to control for both conditions, and 2) how having additional cardiovascular disease (CVD) risk factors is associated with health system performance along the care continuum for diabetes, hypertension, and co-morbid diabetes and hypertension.
Methods
Using a nationally representative household survey carried out in 2015 and 2016 among women aged 15-49 years and men aged 15-54 years, we created a 'cascade of care' for diabetes, hypertension, and co-morbid diabetes and hypertension by determining the proportion of those with the condition who had been diagnosed, were on treatment, and achieved control. We used Poisson regression with a robust error structure to estimate how having additional cardiovascular disease (CVD) risk factors (diabetes, hypertension, current smoking, and obesity) was associated with reaching each cascade step for diabetes, hypertension, and co-morbid diabetes and hypertension.
Findings
Seven hundred thirty-four thousand seven hundred ninety-four adults were included in the analysis. Among individuals with co-morbid diabetes and hypertension, 28·8% (95% CI, 26·7%-31·0%), 16·1% (95% CI, 14·4%-17·9%), and 3·7% (95% CI, 2·8%-4·9%) - with these proportions varying between states by a factor of 4·8, 7·9, and 56·8 - were aware, treated, and achieved control of both conditions, respectively. Men, adults with lower household wealth, and those living in rural areas were less likely to reach each cascade step. Having additional CVD risk factors generally did not increase the probability of reaching each cascade step for diabetes, hypertension, and co-morbid diabetes and hypertension, except that having concurrent diabetes increased the probability of successfully transitioning through the hypertension care cascade.
Interpretation
While varying widely between states and population groups, health system performance for co-morbid diabetes and hypertension is generally low in India, and there appears to be little integration of care across CVD risk factors.
Funding
European Research Council.
Identifiants
pubmed: 35174048
doi: 10.5334/gh.1056
pmc: PMC8815445
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
Copyright: © 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
BMJ. 2004 Apr 3;328(7443):807-10
pubmed: 15070638
N Engl J Med. 2007 Jun 14;356(24):2496-504
pubmed: 17568030
Clin Infect Dis. 2005 Aug 1;41(3):281-8
pubmed: 16007521
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
PLoS One. 2015 Jul 08;10(7):e0127199
pubmed: 26154083
PLoS Med. 2018 Jun 19;15(6):e1002581
pubmed: 29920517
Lancet Glob Health. 2018 Nov;6(11):e1196-e1252
pubmed: 30196093
Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596
pubmed: 28601585
Indian Heart J. 2017 Jul - Aug;69(4):539-544
pubmed: 28822528
Med Care. 2007 Jun;45(6):480-8
pubmed: 17515774
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Lancet. 2015 Apr 11;385(9976):1397-405
pubmed: 25579834
Lancet. 2017 Sep 16;390(10100):1345-1422
pubmed: 28919119
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Bull World Health Organ. 2014 Dec 1;92(12):850
pubmed: 25552765
Heart Asia. 2017 Sep 14;9(2):e010931
pubmed: 29469903
J Am Coll Cardiol. 2018 May 15;71(19):2199-2269
pubmed: 29146533
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
BMJ. 2009 May 19;338:b1665
pubmed: 19454737
Ann Intern Med. 2015 Feb 3;162(3):184-91
pubmed: 25531552
J Public Health (Oxf). 2019 Mar 1;41(1):80-89
pubmed: 29425313
BMC Health Serv Res. 2014 Oct 02;14:451
pubmed: 25274447
JAMA Intern Med. 2018 Mar 1;178(3):363-372
pubmed: 29379964
Demography. 2001 Feb;38(1):115-32
pubmed: 11227840
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Lancet. 2016 Nov 19;388(10059):2532-2561
pubmed: 27616593
Am J Epidemiol. 2004 Apr 1;159(7):702-6
pubmed: 15033648
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Lancet. 2019 Jun 1;393(10187):2233-2260
pubmed: 31030984
Diabetes Care. 2011 Jun;34(6):e61-99
pubmed: 21617108
PLoS Med. 2017 Sep 29;14(9):e1002395
pubmed: 28961237
J Hypertens. 2014 Jun;32(6):1170-7
pubmed: 24621804
BMJ Open. 2015 Oct 07;5(10):e007235
pubmed: 26446164
Lancet. 2018 Jul 28;392(10144):312-358
pubmed: 30032975
Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64
pubmed: 29222377
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
N Engl J Med. 2018 Aug 16;379(7):633-644
pubmed: 30110583
J Hypertens. 2019 Sep;37(9):1822-1831
pubmed: 31368919
N Engl J Med. 2014 Aug 28;371(9):818-27
pubmed: 25162888
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
Lancet Diabetes Endocrinol. 2015 Feb;3(2):114-22
pubmed: 25483220
J Clin Hypertens (Greenwich). 2014 Jan;16(1):14-26
pubmed: 24341872